Stability indicating methods for the determination of diloxanide furoate

被引:13
作者
Hasan, NY [1 ]
Elkawy, MA [1 ]
Elzeany, BE [1 ]
Wagieh, NE [1 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Analyt Chem, Cairo, Egypt
关键词
diloxanide furoate; derivative spectrophotometry; RSD1; spectrophotometry; pH-induced difference spectrophotometry; thin-layer chromatographic densitometry; reversed phase high performance liquid chromatography;
D O I
10.1016/S0731-7085(01)00583-0
中图分类号
O65 [分析化学];
学科分类号
070302 [分析化学]; 081704 [应用化学];
摘要
Five new selective, precise and accurate methods are described for the determination of diloxanide furoate (DI) in presence of its degradation products. Method A utilizes the first and second derivative spectrophotometry at 270 and 280 nm, respectively. Method B is a RSD, spectrophotometric method based on the simultaneous use of the first derivative of ratio spectra and measurement at 270 nm. Method C is a pH-induced difference spectrophotometry using UV measurement at 295 run. Method D is a densitometric one, after separation on silica gel plate using chloroform: methanol as mobile phase and the spots were scanned at 258 nm. Method E is reversed phase high performance liquid chromatography using methanol: water (80:20%) v/v) as mobile phase at a Row rate of 1 ml/min and UV detection at 258 nm. Regression analysis showed good correlation in the concentration ranges 5-30, 5-25, 10-40 mug/ml, 100 -500 ng/spot, 2-50 mug/ml with percentage recoveries of 99.92 +/- 0.56 and 99.79 +/- 0.47, 99.23 +/- 038, 99.96 +/- 0.06, 99.03 +/- 0.51, 98.81 +/- 0.68 for methods A, B, C, D and E, respectively. These methods are suitable as stability indicating methods for the determination of DI in presence of its degradation products either in bulk powder or in pharmaceutical formulations. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:187 / 197
页数:11
相关论文
共 26 条
[1]
Das T. K., 1992, INDIAN DRUGS, V29, P165
[2]
HPLC ANALYSIS OF METRONIDAZOLE AND DILOXANIDE FUROATE IN ITS DOSAGE FORMS [J].
ELGIZAWY, SM .
ANALYTICAL LETTERS, 1995, 28 (01) :83-92
[3]
Galal S M, 1991, J Pharm Belg, V46, P315
[4]
DILOXANIDE FUROATE FOR TREATING ASYMPTOMATIC ENTAMOEBA-HISTOLYTICA CYST PASSERS - 14 YEARS EXPERIENCE IN THE UNITED-STATES [J].
MCAULEY, JB ;
HERWALDT, BL ;
STOKES, SL ;
BECHER, JA ;
ROBERTS, JM ;
MICHELSON, MK ;
JURANEK, DD .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (03) :464-468
[5]
MOFFAT AC, 1986, CLARKES ISOLATION ID, P548
[6]
Simultaneous quantitative determination of metronidazole and diloxanide furoate in a tablet preparation by difference spectroscopy [J].
Parimoo, P ;
Prasad, CVN ;
Gautam, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 134 (1-2) :231-234
[7]
SIMULTANEOUS QUANTITATIVE-DETERMINATION OF TINIDAZOLE AND DILOXANIDE FUROATE IN TABLET PREPARATIONS BY DIFFERENCE SPECTROSCOPY [J].
PARIMOO, P ;
UMAPATHI, P .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1994, 20 (13) :2143-2150
[8]
Podder G., 1989, J I CHEM, V61, P181
[9]
RAO GR, 1983, INDIAN DRUGS, V20, P455
[10]
Ray S, 1989, E PHARM, V32, P125